Ireland
--:--IST
Latest
Clinical Trials in Israel / NCT00264602
Active, not recruiting Phase 1

Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer

NCT00264602 · tracked via the Priya Life Science Israel tracker
Phase
Phase 1
Started
2009-02-18
Last updated
2025-11-10

Condition(s) studied

Lung Cancer

Investigational drug(s) / intervention(s)

Near Infrared Imaging

Near Infrared Imaging: Dye injected into or around tumor at the time of surgery

Study summary

The primary purpose of this study is to determine if we can identify the first lymph node that drains from the tumor, and thus would be the most likely site for metastatic disease, and remove it for analysis to improve the ability to detect tumor in this node and to remove this additional site that potentially contains tumor cells.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Suspected or histologically documented new non-small cell carcinoma that have agreed to undergo a thoracotomy for segmentectomy, lobectomy, bilobectomy or pneumonectomy as recommended by their thoracic surgeon for treatment * Surgically resectable lung cancer * N2 lymph nodes negative on PET scan or mediastinoscopy * Age \> or equal to 18 years of age * Men, women of non-child bearing age or women with a negative pregnancy test Exclusion Criteria: * Patient does not want to undergo subsequent surgical resection * Medical condition such as uncontrolled infection or cardiac disease that, i the opinion of the treating surgeon, makes resection unreasonably hazardous for the patient. * T4 or N2 disease * Pre-operative spirometry that suggests they cannot undergo resection of their primary tumor by segmentectomy, lobectomy, bilobectomy, or pneumonectomy * Iodide or seafood allergy * Pregnant or lactating women

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Massachusetts General Hospital Boston Massachusetts
Beth Israel Deaconess Medical Center Boston Massachusetts
Brigham and Women's Hospital Boston Massachusetts
Dana-Farber Cancer Institute Boston Massachusetts

More Dana-Farber Cancer Institute trials in Israel

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00264602 on ClinicalTrials.gov ↗ ← All trials in Israel